Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Auteur de référence en rhumatologie
29 articles scientifiques publiés — un praticien à la pointe de la recherche
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
59
59 articles ont été cités au moins 59fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
h-index
Total citations reçues
12 851
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
421
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
144
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Université Paris Sciences et Lettres · École Normale Supérieure - PSL · Hôpital Foch
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12
2026ArticleEuropean Journal of Cancer
Vaccine refusal in cancer patients at the French hospital: a normative re-analysis through a 'neopotterian theory of global bioethics
2025ArticleMonash Bioethics Review
Bio-ethical issues in oncology during the first wave of the COVID-19 epidemic: A qualitative study in a French hospital
2023ArticleJournal of Evaluation in Clinical Practice
Very Long‐Term Complete Remission Can Be Achieved in Men With High‐Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial
2023ArticleClinical Genitourinary Cancer
Impact de la pandémie de la COVID-19 sur l’hôpital : l’apport de la bioéthique
2022ArticleMedecine de Catastrophe Urgences Collectives
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial
2022ArticleLancet Oncology
Letter comments on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single-centre prospective study
2022ArticleEuropean Journal of Cancer
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study
2021ArticleClinical Genitourinary Cancer
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
PURPOSE Patients with metastatic urothelial carcinoma (mUC) who progress on platinum-based combination chemotherapy (PLT) and checkpoint inhibitors (CPIs) have limited options that offer objective response rates (ORRs) of approximately 10% with a median overall survival (OS) of 7-8 months. Sacituzumab govitecan (SG) is a TROP-2–directed antibody-drug conjugate with an SN-38 payload that has shown preliminary activity in mUC. METHODS TROPHY-U-01 (ClinicalTrials.gov identifier: NCT03547973 ) is a multicohort, open-label, phase II, registrational study. Cohort 1 includes patients with locally advanced or unresectable or mUC who had progressed after prior PLT and CPI. Patients received SG 10 mg/kg on days 1 and 8 of 21-day cycles. The primary outcome was centrally reviewed ORR; secondary outcomes were progression-free survival, OS, duration of response, and safety. RESULTS Cohort 1 included 113 patients (78% men; median age, 66 years; 66.4% visceral metastases; median of three [range, 1-8] prior therapies). At a median follow-up of 9.1 months, the ORR was 27% (31 of 113; 95% CI, 19.5 to 36.6); 77% had decrease in measurable disease. Median duration of response was 7.2 months (95% CI, 4.7 to 8.6 months), with median progression-free survival and OS of 5.4 months (95% CI, 3.5 to 7.2 months) and 10.9 months (95% CI, 9.0 to 13.8 months), respectively. Key grade ≥ 3 treatment-related adverse events included neutropenia (35%), leukopenia (18%), anemia (14%), diarrhea (10%), and febrile neutropenia (10%), with 6% discontinuing treatment because of treatment-related adverse events. CONCLUSION SG is an active drug with a manageable safety profile with most common toxicities of neutropenia and diarrhea. SG has notable efficacy compared with historical controls in pretreated mUC that has progressed on both prior PLT regimens and CPI. The results from this study supported accelerated approval of SG in this population.
The New England journal of medicine · 2023
The Lancet. Oncology · 2022
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Communications medicine · 2025 · Journal Article
Boué A, Baciarello G, Meyer E, Christy F, et al.
European urology · 2025 · Journal Article
Galsky MD, van der Heijden MS, Powles T, Claps M, et al.
Future oncology (London, England) · 2025 · Journal Article
van der Heijden MS, Sonpavde G, Powles T, Necchi A, et al.
The New England journal of medicine · 2023 · Comparative Study
van der Heijden MS, Sonpavde G, Powles T, Necchi A, et al.
Journal of translational medicine · 2023 · Letter
Stoeklé HC, Billard D, Bennouna J, Beuzeboc P, et al.
Journal of evaluation in clinical practice · 2023 · Journal Article
Stoeklé HC, Ladrat L, Landrin T, Beuzeboc P, et al.
Bulletin du cancer · 2023 · Letter
Sabouret A, Beuzeboc P
BMC medical ethics · 2022 · Journal Article
Stoeklé HC, Sekkate S, Angellier E, Kennel T, et al.
European urology · 2022 · Journal Article
Baciarello G, Delva R, Gravis G, Tazi Y, et al.
European journal of cancer (Oxford, England : 1990) · 2021 · Letter
Stoeklé HC, Sekkate S, Angellier E, Hervé C, et al.
European journal of cancer (Oxford, England : 1990) · 2020 · Published Erratum
Delanoy N, Hardy-Bessard AC, Efstathiou E, Moulec SL, et al.
European journal of cancer (Oxford, England : 1990) · 2020 · Published Erratum
Delanoy N, Hardy-Bessard AC, Efstathiou E, Le Moulec S, et al.
European journal of cancer (Oxford, England : 1990) · 2020 · Case Reports
Laurain PA, Landrin T, Souidi S, Beuzeboc P, et al.
European journal of cancer (Oxford, England : 1990) · 2020 · Journal Article
Delanoy N, Hardy-Bessard AC, Efstathiou E, Le Moulec S, et al.
Joint bone spine · 2019 · Journal Article
Briot K, Paccou J, Beuzeboc P, Bonneterre J, et al.
European urology · 2018 · Clinical Trial, Phase III
Lavaud P, Gravis G, Foulon S, Joly F, et al.
Drug design, development and therapy · 2017 · Journal Article
Deshayes E, Roumiguie M, Thibault C, Beuzeboc P, et al.
Monash bioethics review · 2025 · Published Erratum
Stoeklé HC, Sekkate S, Bennouna J, Beuzeboc P, et al.
Monash bioethics review · 2025 · Letter
Stoeklé HC, Sekkate S, Bennouna J, Beuzeboc P, et al.
Prostate cancer and prostatic diseases · 2020 · Journal Article
Ratta R, Guida A, Scotté F, Neuzillet Y, et al.
The Lancet. Oncology · 2022 · Clinical Trial, Phase II
Vano YA, Elaidi R, Bennamoun M, Chevreau C, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 · Clinical Trial, Phase II
Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, et al.
Prostate cancer and prostatic diseases · 2024 · Journal Article
Jones RH, Fizazi K, James ND, Tammela TL, et al.
Current oncology (Toronto, Ont.) · 2022 · Journal Article
Dang E, Vallée A, Lepage-Seydoux C, Sejean K, et al.
European journal of cancer (Oxford, England : 1990) · 2022 · Letter
Prostate cancer and prostatic diseases · 2020 · Journal Article
Ratta R, Guida A, Scotté F, Neuzillet Y, et al.
European urology focus · 2018 · Comparative Study
Lamy PJ, Allory Y, Gauchez AS, Asselain B, et al.
The Lancet. Oncology · 2022 · Clinical Trial, Phase II
Vano YA, Elaidi R, Bennamoun M, Chevreau C, et al.
Clinical genitourinary cancer · 2021 · Journal Article
Culine S, Fléchon A, Gravis G, Roubaud G, et al.
Clinical genitourinary cancer · 2023 · Randomized Controlled Trial
Orlando V, Drubay D, Lavaud P, Faivre L, et al.
European urology focus · 2018 · Comparative Study
Lamy PJ, Allory Y, Gauchez AS, Asselain B, et al.
JAMA oncology · 2019 · Clinical Trial, Phase III
Oudard S, Latorzeff I, Caty A, Miglianico L, et al.
Sekkate S, Stoeklé HC, Mabro M, Billard D, et al.